Research programme: infectious disease vaccines - TapImmune

Drug Profile

Research programme: infectious disease vaccines - TapImmune

Alternative Names: Smallpox vaccine - TapImmune; TPIV-300; TPIV-301

Latest Information Update: 29 Feb 2016

Price : $50

At a glance

  • Originator TapImmune
  • Developer Mayo Clinic; TapImmune
  • Class Vaccines
  • Mechanism of Action Major histocompatibility complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Smallpox; Viral infections

Most Recent Events

  • 18 Feb 2016 TapImmune receives patent allowance for PolyStart™ in USA
  • 29 Oct 2014 Research programme: infectious disease vaccines - TapImmune is available for licensing as of 22 Oct 2014. http://www.tapimmune.com/
  • 22 Oct 2014 Pharmacodynamics data from a preclinical trial in Smallpox released by TapImmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top